AU2194895A - Composition and methods for creating syngeneic recombinant virus-producing cells - Google Patents

Composition and methods for creating syngeneic recombinant virus-producing cells

Info

Publication number
AU2194895A
AU2194895A AU21948/95A AU2194895A AU2194895A AU 2194895 A AU2194895 A AU 2194895A AU 21948/95 A AU21948/95 A AU 21948/95A AU 2194895 A AU2194895 A AU 2194895A AU 2194895 A AU2194895 A AU 2194895A
Authority
AU
Australia
Prior art keywords
syngeneic
creating
composition
methods
producing cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21948/95A
Inventor
David T Curiel
Robert I. Garver Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Publication of AU2194895A publication Critical patent/AU2194895A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
AU21948/95A 1994-03-25 1995-03-24 Composition and methods for creating syngeneic recombinant virus-producing cells Abandoned AU2194895A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21821794A 1994-03-25 1994-03-25
US218217 1994-03-25
PCT/US1995/003729 WO1995026411A2 (en) 1994-03-25 1995-03-24 Composition and methods for creating syngeneic recombinant virus-producing cells

Publications (1)

Publication Number Publication Date
AU2194895A true AU2194895A (en) 1995-10-17

Family

ID=22814221

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21948/95A Abandoned AU2194895A (en) 1994-03-25 1995-03-24 Composition and methods for creating syngeneic recombinant virus-producing cells

Country Status (2)

Country Link
AU (1) AU2194895A (en)
WO (1) WO1995026411A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1548118A2 (en) 1994-06-10 2005-06-29 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
AU731767B2 (en) 1995-06-15 2001-04-05 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
FR2741358B1 (en) * 1995-11-17 1998-01-02 Centre Nat Rech Scient PRODUCTION OF RETROVIRAL VECTORS VIA DNA VIRUS-BASED VIRAL VECTORS
FR2747046B1 (en) * 1996-04-05 1998-06-19 Univ Paris Curie NEW PLASMOVIRUS VACCINES
US6027721A (en) * 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
IL155726A0 (en) 2000-12-28 2003-11-23 Wyeth Corp Recombinant protective protein from streptococcus pneumoniae
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7648772B2 (en) * 2005-06-28 2010-01-19 International Paper Co. Moisture resistant container
AR064642A1 (en) 2006-12-22 2009-04-15 Wyeth Corp POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD
EP2356135B1 (en) 2008-11-05 2017-10-25 Wyeth LLC Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
DK3246044T3 (en) 2010-08-23 2021-01-18 Wyeth Llc Stable formulations of Neisseria meningitidis RLP2086 antigens
EP3549601B1 (en) 2010-09-10 2021-02-24 Wyeth LLC Non-lipidated variants of neisseria meningitidis orf2086 antigens
EA033803B1 (en) 2012-02-07 2019-11-27 Global Bio Therapeutics Inc Compartmentalized method of nucleic acid delivery, compositions and uses thereof
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
SG10201602558UA (en) 2012-03-09 2016-05-30 Pfizer Neisseria meningitidis compositions and methods thereof
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
CA2940513C (en) 2013-03-11 2023-08-15 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for ocular inflammation
EP3030163B1 (en) 2013-08-08 2019-03-20 Global Bio Therapeutics, Inc. Clamp device for minimally invasive procedures
KR20180099912A (en) 2013-09-08 2018-09-05 화이자 인코포레이티드 Neisseria meningitidis compositions and methods thereof
US11053291B2 (en) 2014-02-19 2021-07-06 University Of Florida Research Foundation, Incorporated Delivery of Nrf2 as therapy for protection against reactive oxygen species
CN107249626A (en) 2015-02-19 2017-10-13 辉瑞大药厂 Neisseria meningitidis composition and its method
BR112019014397A2 (en) 2017-01-31 2020-02-11 Pfizer Inc. COMPOSITIONS OF NEISSERIA MENINGITIDIS AND METHODS OF THE SAME
EP4340855A1 (en) 2021-08-13 2024-03-27 Triovance Holding LLC A skin substitute composition and methods of producing and using the same
WO2023225160A1 (en) 2022-05-18 2023-11-23 The Children's Hospital Of Philadelphia Compositions and methods for inducible alternative splicing regulation of gene expression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
AU1648092A (en) * 1992-03-19 1993-10-21 Cancer Research Campaign Technology Limited Defective recombinant adenoviruses expressing characteristic epstein-barr virus proteins

Also Published As

Publication number Publication date
WO1995026411A3 (en) 1996-07-18
WO1995026411A2 (en) 1995-10-05

Similar Documents

Publication Publication Date Title
AU2194895A (en) Composition and methods for creating syngeneic recombinant virus-producing cells
AU9397098A (en) Methods and cell line useful for production of recombinant adeno-associated viruses
AU5081298A (en) Surgical method and composition therefor
AU4907897A (en) Therapeutic liposome composition and method
AU2589095A (en) Cell membrane fusion composition and method
AU4008495A (en) Tcl-1 gene and protein and related methods and compositions
AU5377598A (en) Composition and method for preserving progenitor cells
AU4655296A (en) Compositions and methods for treating tumor cells
AU3131997A (en) Process for preparing copolymers and blend compositions containing the same
AU6136094A (en) Apolipoprotein b mrna editing protein compositions and methods
EP0788165A3 (en) Storage cell arrangement and method for making the same
AU4012997A (en) Method and composition for incorporating radiation-absorbing agents into polymers
AU3154295A (en) Method for preserving cells, and uses of said method
AUPO976797A0 (en) Method and composition (III)
AU4048395A (en) Deinking composition and process
AU6043396A (en) Composition and methods for creating syngeneic recombinant v irus-producing cells
AU2259897A (en) Methods and compositions for the simultaneous control of rootdiseases
AUPO976597A0 (en) Method and composition (I)
AU2195095A (en) Devices and methods for implanting transduced cells
AU9508998A (en) Methods and compositions for binding hematopoietic stem cells
AU3461095A (en) Compositions and methods for delivery of polypeptides
AU6229498A (en) Composition for gene introduction into cell
AU5432798A (en) Materials and procedures for the purification of cells
AU9301998A (en) Composition and methods using galectin-1
AU2100997A (en) Composition containing iso-flavonoids and lignans